Edition:
United Kingdom

Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

15.95USD
20 Jun 2018
Change (% chg)

$0.05 (+0.31%)
Prev Close
$15.90
Open
$15.90
Day's High
$16.12
Day's Low
$15.75
Volume
214,060
Avg. Vol
335,210
52-wk High
$24.45
52-wk Low
$8.15

Chart for

About

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of... (more)

Overall

Beta: 1.45
Market Cap(Mil.): $1,380.17
Shares Outstanding(Mil.): 59.75
Dividend: --
Yield (%): --

Financials

  DVAX.OQ Industry Sector
P/E (TTM): -- 82.81 32.74
EPS (TTM): -2.48 -- --
ROI: -72.82 2.00 14.38
ROE: -73.07 3.49 16.08

BRIEF-Dynavax Reports Q1 Loss Per Share Of $0.63

* Q1 EARNINGS PER SHARE VIEW $-0.49 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

08 May 2018

BRIEF-Dynavax Technologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

* DYNAVAX TECHNOLOGIES CORPORATION ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Source text for Eikon: Further company coverage:

07 May 2018

BRIEF-Dynavax Provides New Durability Of Response Data For SD-101 In Combination With Keytruda In Melanoma

* DYNAVAX PROVIDES NEW DURABILITY OF RESPONSE DATA FOR SD-101 IN COMBINATION WITH KEYTRUDA (PEMBROLIZUMAB) IN MELANOMA AT THE 2018 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

17 Apr 2018

BRIEF-Dynavax Qtrly Loss Per Share $0.45

* DYNAVAX REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

08 Mar 2018

BRIEF-Dynavax Secures $175 Million In Non-Dilutive Debt Financing

* DYNAVAX SECURES $175 MILLION IN NON-DILUTIVE DEBT FINANCING

20 Feb 2018

BRIEF-Dynavax Says Heplisav-B Available In U.S. For Prevention Of Hepatitis B In Adults

* DYNAVAX ANNOUNCES HEPLISAV-B™ IS NOW AVAILABLE IN THE UNITED STATES FOR THE PREVENTION OF HEPATITIS B IN ADULTS Source text for Eikon: Further company coverage:

08 Jan 2018

Earnings vs. Estimates